2Solomon IH, Ramkissoon SH, Milner DA Jr, et al. Cyto- megalovirus and glioblastoma: a review of evidence for their association and indications for testing and treatment [J]. J Neuropathol Exp Neurol, 2014,73 ( 11 ) : 994-998.
3Olson J J, Nayak L, Ormond DR, et al. The role of targeted therapies in the management of progressive glioblastoma.. a systematic review and evidence-based clinical practice guideline[J]. J Neurooncol, 2014,118(3) : 557-599.
4Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, et al. The NFkappaB pathway:a therapeutic target in glioblas- toma[J]. Oncotarget,2011,2(8) :646-653.
5Waelchli R, Bollbuck B, Bruns C, et al. Design and prepa- ration of 2-benzamido-pyrimidines as inhibitors of IKK [J]. Bioorg Med Chem Lett, 2006,16(1) : 108-112.
6Omuro A, DeAngelis LM. Glioblastoma and other malig- nant gliomas .. a clinical review[J]. JAMA, 2013,310 ( 17 ) : 1842-1850.
7Munson J,Bonner M,Fried L,et al. Identifying new small molecule anti-invasive compounds for glioma treatment [J]. Cell Cycle, 2013,12 (14) : 2200-2209.
8Atkinson GP, Nozell SE, Benveniste ET. NF-kappaB and STAT3 signaling in glioma: targets for future therapies [J]. Expert Rev Neurother, 2010,10 (4) : 575-586.
9Robe PA, Bentires-Alj M, Bonif M, et al. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sul- fasalazine in human glioblastomas[J]. Clin Cancer Res, 2004,10(16) : 5595-5603.
10Kauppinen A, Suuronen T, Ojala J, et al. Antagonistic erosstalk between NF kappaB and SIRT1 in the regulation of inflamma- tion and metabolic disorders[J]. Cell Signal, 2013,25(10) :1939- 1948.
